Clinical Trial of OV101 in Pediatric Patients
06 Dec

Clinical Trial of OV101 in Pediatric Patients

On December 6, 2018, Ovid Therapeutics announced plans to move ahead with a single, pivotal Phase 3 trial of once-daily dosing of OV101 in pediatric patients with Angelman syndrome. This is based on its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA). If successful, the Phase 3 efficacy and safety trial is intended to support a New Drug Application (NDA) for OV101 in AS.

 

Read the full announcement from Ovid Therapeutics.

Leave a Reply